Journal of Okayama Medical Association
Published by Okayama Medical Association

Full-text articles are available 3 years after publication.

癌化学療法による宿主造血能抑制の防止に関する基礎的研究 第2編 諸種免疫賦活剤[Bestatin,溶連菌製剤OK-432,有機化合物Carboxyethylgermanium Sesquioxide(Ge-132)]による造血能賦活効果の比較検討

内田 耕三郎 岡山大学医学部第2内科
99_633.pdf 1.01 MB
The hemopoietic potentials of three immunomodulators, Bestatin, OK-432 and Ge-132, were compared in terms of the effects of the drugs on the recovery from cyclophosphamide (CPA)-induced myelosuppression, and on autologous CFUs in irradiated mice. The recovery from CPA-induced myelosuppression was significantly accelerated in mice pretreated with Bestatin or OK-432 as compared to mice pretreated with Ge-132 or physiological saline. The effect of OK-432 was somewhat superior to that of Bestatin, but there were no significant differences in the days to nadir and in the days required for the recovery from nadir. Both Bestatin and OK-432 significantly increased the number of autologous CFUs in irradiated mice as compared to Ge-132 and Lentinan. Most chemotherapeutic schedules are divided into four therapeutic phases : induction, consolidation, maintenance and intensification. The last two phases were usually applied to outpatients ; therefore, hemopoietic agents, such as Bestatin, which can be orally administrated, may be useful clinically for the prevention of chronic myelosuppression during maintenance and intensification chemotherapy.
Myelosuppression by cancer chemotherapy
Hemopoietic potentials of immunomodulators